Detection of Chromosomal Translocation Transcripts with Molecular Beacons

用分子信标检测染色体易位转录本

• 批准号: 7327862
• 负责人: THANH N DOAN
• 金额: $ 15.83万
• 依托单位: VIVONETICS, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-24 至 2009-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7327862
• 关键词: Actins; Acute Lymphocytic Leukemia; Acute Myelocytic Leukemia; Cancer Detection; Cell Line; Cell Separation; Cells; Chromosomal translocation; Chronic Myeloid Leukemia; Clinical; Data; Detection; Diagnosis; Diagnostic; Flow Cytometry; Fluorescence Microscopy; Fluorescence Resonance Energy Transfer; Genes; Housekeeping; Housekeeping Gene; Individual; Jurkat Cells; K-562; K562 Cells; Label; Leukemic Cell; Life; Malignant Neoplasms; Messenger RNA; Methods; Molecular; Mutation; Noise; Normal Cell; Oncogenes; Phase; Philadelphia Chromosome; Physicians; Polymerase Chain Reaction; Population; Protein Isoforms; Purpose; Relative (related person); Sampling; Signal Transduction; Staging; Technology; Testing; Time; Transcript; Variant; base; cancer cell; cancer diagnosis; cancer type; commercialization; design; improved; leukemia; mouse model; novel; research study; success; tool

DESCRIPTION (provided by applicant): The purpose of this Phase I proposal is to demonstrate that molecular beacons can be exploited to detect oncogenes that result from chromosomal translocation, a phenomenon commonly found in some types of cancer. The success of using molecular beacon technology will enable the ability to screen for individual cancer cells and thereby increasing the sensitivity for the detection of cancer. Commercialization: The molecular beacons that specifically recognize oncogenes will be tested in mice models harboring the oncogene and in clinical cancer samples. Molecular beacons will be valuable tools for detecting and diagnosing cancer. The success of these studies will provide an improved method to diagnose cancer that is a result of chromosomal translocation. The enhanced sensitivity provided by molecular beacon technology will enable physicians to treat for cancer at earlier stages.

描述（由申请人提供）：本I期提案的目的是证明分子信标可用于检测染色体易位导致的癌基因，这是某些类型癌症中常见的现象。使用分子信标技术的成功将使筛选单个癌细胞的能力成为可能，从而提高检测癌症的灵敏度。商业化：特异性识别癌基因的分子信标将在携带癌基因的小鼠模型和临床癌症样本中进行测试。分子信标将成为检测和诊断癌症的宝贵工具。这些研究的成功将为诊断染色体易位导致的癌症提供一种改进的方法。分子信标技术提供的增强的灵敏度将使医生能够在早期阶段治疗癌症。